Clonidine Versus Tranexamic Acid in Reduction of Blood Loss

Overview

Tranexamic acid is an antifibrinolytics agent that has been widely used in the reduction of blood loss at surgeries. Oral clonidine is an alpha-2 adrenergic agonist that has been used in various surgeries including Caesarean section.

Full Title of Study: “Premedication With Oral Clonidine Versus Intraoperative Intravenous Tranexamic Acid in Reduction of Blood Loss During Elective Cesarean Section in Abakaliki – a Randomized Control Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: August 3, 2022

Detailed Description

SUMMARY Background: Primary postpartum haemorrhage is a leading cause of maternal mortality and morbidity. Prevention of excessive blood loss at caesarean section is of utmost concern to the obstetrician. Blood sparing modalities are useful in the reduction of the amount of blood loss at the caesarean section. Tranexamic acid is an antifibrinolytics agent that has been widely used in the reduction of blood loss at surgeries. Oral clonidine is an alpha-2 adrenergic agonist that has been used in various surgeries including Caesarean section through its controlled hypotensive effect to reduce blood loss. Objective: This study is designed to compare the effectiveness of Premedication with oral clonidine versus intravenous tranexamic acid in the reduction of blood loss during elective caesarean section in Abakaliki. Methodology: This would be an equivalence double-blind, double-dummy randomized controlled clinical trial among parturients undergoing elective caesarean section in Abakaliki.This will involve 112 pregnant women at term for elective caesarean section. They will be randomized into two arms(56 Parturients in each arm). Group A will receive 100mg of tablet Vitamin C (placebo) and 1gram of intravenous tranexamic acid. Group B will receive 0.2mg of oral clonidine 60 minutes before surgery and 10mls of sterile water (placebo) 10 minutes after skin incision. The data obtained will be analysed using a statistical package for service solutions (Version 20, Chicago II, USA) and the Consolidated standard of reporting trials with the intention to treat will be applied. Continuous variables would be presented as mean and standard deviation (Mean +SD), while categorical variables would be presented as numbers and percentages. Relative Risk and logistic regression will be applied where necessary. A difference with a P-value of <0.05 will be taken to be statistically significant. Results: The results will be presented in tables from where conclusions will be drawn. Conclusion and Recommendation: This Will be drawn from the result. Keyword Blood loss, Tranexamic acid, Clonidine, Caesarean section.

Interventions

  • Drug: clonidine group
    • Each participant will be receive 0.2mg of oral clonidine 60 minutes before surgery and 10mls of sterile water (placebo) 10 minutes after skin incision

Arms, Groups and Cohorts

  • Active Comparator: Tranexamic acid
    • Each participant will receive 1gram of tranexamic acid
  • Active Comparator: clonidine
    • Each participant will receive 0.2mg of oral clonidine

Clinical Trial Outcome Measures

Primary Measures

  • Blood loss
    • Time Frame: 6 months
    • Estimated blood loss following Caesarean Section

Secondary Measures

  • Bleeding tendency
    • Time Frame: 6 months
    • Change in haematocrit 48 hours after delivery

Participating in This Clinical Trial

Inclusion Criteria

  • Participants for the study include consenting parturients with singleton pregnancy at 37-42 weeks gestational age,admitted for elective caesarean section. Exclusion Criteria:

  • Prior history of thromboembolism or bleeding disorder – Renal disease – Liver disease – Antepartum Hemorrhage – Intrauterine Growth restricted fetuses – Patient refusal

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Uwakwe Emmanuel Chijioke
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Uwakwe Emmanuel Chijioke, Principal Investigator – Alex Ekwueme Federal University Teaching Hospital
  • Overall Official(s)
    • Uwakwe DR Emmanuel Chijioke, PART 1, Principal Investigator, Alex Ekwueme Federal University Teaching Hospital
  • Overall Contact(s)
    • UGOJI DR DARLINGTON-PETER, PART 1, 0806 874 8644, darlingtonpeter2012@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.